Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cresco Labs (CRLBF) EBT (2020 - 2026)

Cresco Labs filings provide 7 years of EBT readings, the most recent being -$2.8 million for Q1 2026.

  • On a quarterly basis, EBT fell 204.36% to -$2.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$97.3 million, a 254.04% decrease, with the full-year FY2025 number at -$95.4 million, down 798.85% from a year prior.
  • EBT hit -$2.8 million in Q1 2026 for Cresco Labs, up from -$87.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $15.9 million in Q1 2024 to a low of -$156.9 million in Q4 2022.
  • Median EBT over the past 5 years was -$918000.0 (2025), compared with a mean of -$22.5 million.
  • Biggest five-year swings in EBT: surged 244.94% in 2024 and later tumbled 2952.54% in 2025.
  • Cresco Labs' EBT stood at -$156.9 million in 2022, then surged by 108.17% to $12.8 million in 2023, then crashed by 76.17% to $3.1 million in 2024, then tumbled by 2952.54% to -$87.1 million in 2025, then surged by 96.79% to -$2.8 million in 2026.
  • The last three reported values for EBT were -$2.8 million (Q1 2026), -$87.1 million (Q4 2025), and -$10.1 million (Q3 2025) per Business Quant data.